AU2002329423B2 - Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex - Google Patents

Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex Download PDF

Info

Publication number
AU2002329423B2
AU2002329423B2 AU2002329423A AU2002329423A AU2002329423B2 AU 2002329423 B2 AU2002329423 B2 AU 2002329423B2 AU 2002329423 A AU2002329423 A AU 2002329423A AU 2002329423 A AU2002329423 A AU 2002329423A AU 2002329423 B2 AU2002329423 B2 AU 2002329423B2
Authority
AU
Australia
Prior art keywords
ser
gly
antibody
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002329423A
Other languages
English (en)
Other versions
AU2002329423A1 (en
Inventor
Geoffrey Hale
John Isaacs
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9922741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002329423(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU2002329423A1 publication Critical patent/AU2002329423A1/en
Application granted granted Critical
Publication of AU2002329423B2 publication Critical patent/AU2002329423B2/en
Priority to AU2008207338A priority Critical patent/AU2008207338B2/en
Assigned to OXFORD UNIVERSITY INNOVATION LIMITED reassignment OXFORD UNIVERSITY INNOVATION LIMITED Request to Amend Deed and Register Assignors: ISIS INNOVATION LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002329423A 2001-09-26 2002-09-26 Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex Ceased AU2002329423B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008207338A AU2008207338B2 (en) 2001-09-26 2008-08-15 Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123156A GB2380127A (en) 2001-09-26 2001-09-26 Treatment of chronic joint inflammation
GB0123156.2 2001-09-26
PCT/GB2002/004358 WO2003026692A2 (en) 2001-09-26 2002-09-26 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008207338A Division AU2008207338B2 (en) 2001-09-26 2008-08-15 Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex

Publications (2)

Publication Number Publication Date
AU2002329423A1 AU2002329423A1 (en) 2003-06-26
AU2002329423B2 true AU2002329423B2 (en) 2008-05-15

Family

ID=9922741

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002329423A Ceased AU2002329423B2 (en) 2001-09-26 2002-09-26 Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
AU2008207338A Ceased AU2008207338B2 (en) 2001-09-26 2008-08-15 Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008207338A Ceased AU2008207338B2 (en) 2001-09-26 2008-08-15 Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex

Country Status (10)

Country Link
US (1) US20050037004A1 (OSRAM)
EP (3) EP2199307B1 (OSRAM)
JP (1) JP4694784B2 (OSRAM)
AU (2) AU2002329423B2 (OSRAM)
CA (1) CA2461714C (OSRAM)
DE (1) DE60217698T2 (OSRAM)
ES (2) ES2279884T3 (OSRAM)
GB (1) GB2380127A (OSRAM)
PT (1) PT1432445E (OSRAM)
WO (1) WO2003026692A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6660948B2 (en) * 2001-02-28 2003-12-09 Vip Investments Ltd. Switch matrix
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US7883703B2 (en) * 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
CN1972714B (zh) * 2004-04-06 2012-10-03 诺夫免疫股份有限公司 治疗自身免疫疾病和炎性疾病的方法
BRPI0511782B8 (pt) 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
RU2271816C1 (ru) * 2004-07-08 2006-03-20 Григорий Менделевич Дубровин Способ профилактики посттравматического остеоартроза
BRPI0513798A (pt) 2004-07-26 2008-05-13 Biogen Idec Inc anticorpos anti-cd154
US7740856B2 (en) 2005-12-20 2010-06-22 Isu Abxis Co., Ltd. Effect of BST2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007117600A2 (en) * 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
US7927590B2 (en) 2006-07-10 2011-04-19 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
US20120269826A1 (en) * 2009-10-20 2012-10-25 Mckee Charlotte Anti-cd3 antibody dosing in autoimmune disease
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
JP2025509702A (ja) 2022-03-14 2025-04-11 ラムキャップ バイオ ガンマ エージー ＧＰＣ３陽性悪性細胞を標的殺傷するための二重特異性ＧＰＣ３ｘＣＤ２８抗体およびＧＰＣ３ｘＣＤ３抗体ならびにそれらの組み合わせ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005268A1 (en) * 1998-07-21 2000-02-03 Btg International Ltd. Hybrid human/rodent igg antibody to cd3, and methods of its construction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0610447T3 (da) 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
SE510197C2 (sv) 1997-02-06 1999-04-26 Asea Brown Boveri Förfarande och anordning för styrning av ett kondensatordon för en shuntkopplad statisk kompensatorenhet med deblockeringssignaler för indikering av icke strömförande tillstånd hos ingående ventiler
US5843597A (en) * 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
CA2224256C (en) * 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005268A1 (en) * 1998-07-21 2000-02-03 Btg International Ltd. Hybrid human/rodent igg antibody to cd3, and methods of its construction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Malfait et al. 2001, Arthritis and Rheumatism Vol. 44, No. 5, pages 1215-1224 *

Also Published As

Publication number Publication date
DE60217698T2 (de) 2007-10-25
AU2008207338A1 (en) 2008-09-04
JP4694784B2 (ja) 2011-06-08
EP1803466B1 (en) 2012-07-11
US20050037004A1 (en) 2005-02-17
PT1432445E (pt) 2007-03-30
EP2199307B1 (en) 2014-11-05
CA2461714A1 (en) 2003-04-03
WO2003026692A2 (en) 2003-04-03
CA2461714C (en) 2013-03-12
EP1432445A2 (en) 2004-06-30
GB2380127A (en) 2003-04-02
EP1803466A1 (en) 2007-07-04
DE60217698D1 (de) 2007-03-08
ES2279884T3 (es) 2007-09-01
EP2199307A1 (en) 2010-06-23
AU2008207338B2 (en) 2011-12-08
ES2389781T3 (es) 2012-10-31
GB0123156D0 (en) 2001-11-21
WO2003026692A3 (en) 2003-12-18
EP1432445B1 (en) 2007-01-17
JP2005506331A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
AU2008207338B2 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
AU2002329423A1 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
JP4065554B2 (ja) 抗体の調製
EP2265643B1 (en) Dosing regimen for treating psoriasis and rheumatoid arthritis
EP2260057B1 (en) Anti-CD4 antibody dosage regimen for treating autoimmune disease
RU2562874C1 (ru) Антитела против ох40 и способы их применения
AU2023285870A1 (en) Antagonistic anti-canine PD-1 antibodies
JP4629228B2 (ja) ＣＤ３に対するヒト／げっ歯動物ハイブリドＩｇＧ抗体、およびその構築の方法
JP4448906B2 (ja) Ｃｄ４特異的抗体ｔｒｘ１およびその使用
CN102027016A (zh) 一种治疗疾病的试剂
JPH11506310A (ja) Ｂ細胞リンパ腫および細胞株の処置に効果的な二重特異性抗体
HU211626A9 (en) Recombinant antibodies
JP2008503593A (ja) 霊長類で寛容を誘導するための抗ｃｄ４抗体で最適化された投薬
WO2005012494A2 (en) Treatment of organ transplant rejection
GB2376466A (en) TRX1 antibody
CN114729048A (zh) 使用抗ox40抗体与tlr激动剂组合治疗癌症的方法
WO2017076805A1 (en) Use of an inhibitor of il18 for treatment of acute kidney injury
HK1151533B (en) Agent for treating disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired